Reconstructive Technologies Inc.
This article was originally published in Start Up
Executive Summary
For 13,000 severely burned patients in the US each year, and 3 million people with non-healing ulcers due to various causes, there is not enough skin to go around. Reconstructive Technologies Inc. hopes to be able to provide patients with a more plentiful source of full-thickness autograft skin, with a bioreactor that accelerates skin growth.
You may also be interested in...
Skin Repair
A handful of start-ups hopes to fill the cracks in the fragmented market for skin repair. Their approaches vary widely; British start-up Renovo has a pharmaceutical approach to the prevention of scarring. Reconstructive Technologies believes that the best replacement for skin is skin itself; it has developed a bioreactor that accelerates the growth of autograft skin, with both {in vivo} and {in vitro} systems. Artecel Sciences will use adipose-derived stromal cells in cosmesis and hematopoietic support. Niadyne 's platform of unique formulations of niacin lend themselves to a variety of applications, in cosmeceuticals and in cardiovascular disease.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.